We are live on ! Find out more
IMRX icon

Immuneering
IMRX

50 hedge funds and large institutions have $88.1M invested in Immuneering in 2022 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 23 increasing their positions, 6 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,300% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 1

283% more repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 6

35% more funds holding

Funds holding: 37 → 50 (+13)

3.41% more ownership

Funds ownership: 48.19% → 51.6% (+3.4%)

56% less capital invested

Capital invested by funds: $200M → $88.1M (-$112M)

Holders
50
Holders Change
+13
Holders Change %
+35.14%
% of All Funds
0.79%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
14
Increased
23
Reduced
6
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$4.79M
2
BlackRock
BlackRock
New York
+$3.91M
3
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$3.62M
4
Fidelity Investments
Fidelity Investments
Massachusetts
+$1.27M
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$1M

Top Sellers

Rank Fund Capital Flow
1
RSCM
Rock Springs Capital Management
Maryland
-$17.6M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$1.58M
3
Citigroup
Citigroup
New York
-$13.7K
4
Millennium Management
Millennium Management
New York
-$10.4K
5
Allspring Global Investments
Allspring Global Investments
North Carolina
-$9.4K
Name Holding Trade Value Shares
Change 		Change in
Stake
T. Rowe Price Associates
1
T. Rowe Price Associates
Maryland
$23.1M +$3.62M +376,968 +12%
CAM
2
Cormorant Asset Management
Massachusetts
$14.9M – – –
Citadel Advisors
3
Citadel Advisors
Florida
$14M +$973K +101,330 +5%
BlackRock
4
BlackRock
New York
$13.7M +$3.91M +407,204 +24%
Vanguard Group
5
Vanguard Group
Pennsylvania
$5.26M +$4.79M +498,479 +159%
PA
6
Perceptive Advisors
New York
$4.41M – – –
Geode Capital Management
7
Geode Capital Management
Massachusetts
$1.54M +$1M +104,601 +78%
Fidelity Investments
8
Fidelity Investments
Massachusetts
$1.38M +$1.27M +131,818 +161%
SCM
9
Suvretta Capital Management
New York
$1.29M – – –
State Street
10
State Street
Massachusetts
$1.14M +$543K +56,539 +47%
Adage Capital Partners
11
Adage Capital Partners
Massachusetts
$971K -$1.58M -164,000 -52%
Northern Trust
12
Northern Trust
Illinois
$929K +$650K +67,667 +89%
TD Asset Management
13
TD Asset Management
Ontario, Canada
$784K +$835K +86,905 +253%
Manulife (Manufacturers Life Insurance)
14
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$573K +$812K +84,525 New
D.E. Shaw & Co
15
D.E. Shaw & Co
New York
$454K +$674K +70,127 New
KPW
16
Kore Private Wealth
New York
$382K +$393K +40,924 +226%
Renaissance Technologies
17
Renaissance Technologies
New York
$373K +$553K +57,600 New
Two Sigma Investments
18
Two Sigma Investments
New York
$332K +$493K +51,360 New
Bank of New York Mellon
19
Bank of New York Mellon
New York
$314K +$236K +24,556 +103%
Charles Schwab
20
Charles Schwab
California
$295K +$231K +24,044 +112%
N
21
Nuveen
North Carolina
$196K +$147K +15,287 +130%
Bank of America
22
Bank of America
North Carolina
$189K +$207K +21,572 +279%
CSS
23
Cubist Systematic Strategies
Connecticut
$189K +$280K +29,160 New
Millennium Management
24
Millennium Management
New York
$185K -$10.4K -1,087 -4%
JF
25
Jump Financial
Illinois
$125K +$185K +19,300 New
1
2

IMRX Hedge Fund Activity: Q1 2022 in Review

50 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Immuneering (IMRX) for Q1 2022, worth a combined $88.1M — down 56% from $200M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new IMRX positions and 1 closed out — a net gain of 13 holders — while 23 added to existing stakes and 6 trimmed.

The largest buyer was Vanguard Group, adding an estimated $4.79M. The largest seller was Rock Springs Capital Management, exiting entirely with an estimated $17.6M sold.

  • 50 institutional investors held Immuneering (IMRX) as of Q1 2022, up from 37 in Q4 2021.
  • Funds reported $88.1M of Immuneering stock for Q1 2022, down 56% quarter-over-quarter.
  • 14 funds opened new Immuneering positions in Q1 2022 and 1 closed out, a net change of +13 holders.
  • The largest Immuneering buyer in Q1 2022 was Vanguard Group, an estimated $4.79M added.
  • The largest Immuneering seller in Q1 2022 was Rock Springs Capital Management, an estimated $17.6M sold.

Based on aggregated 13F filings for Q1 2022.